In lab-grown cancer cells, those with a specific genetic deletion (9p21 loss) show physical signs of being more damaged by gemcitabine than cells without the deletion, indicating this drug may work better against this cancer subtype.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether patients with 9p21-loss tumors have significantly higher response rates to gemcitabine compared to those without the deletion across multiple clinical trials.
A systematic review and meta-analysis of all published clinical trials (n≥15) evaluating gemcitabine in patients with 9p21-loss versus 9p21-intact tumors, with standardized genetic testing, primary endpoints of objective response rate and progression-free survival, and subgroup analysis by tumor type.
An RCT could determine whether gemcitabine improves survival in patients with 9p21-loss bladder cancer compared to alternative therapies.
A multicenter, double-blind RCT of 250 patients with advanced 9p21-loss bladder cancer randomized to gemcitabine (1000 mg/m² IV weekly × 3 weeks every 4 weeks) vs. alternative standard chemotherapy, with primary endpoint of overall survival at 18 months, confirmed by central genetic testing.
A prospective cohort could determine whether 9p21 loss predicts improved outcomes in patients treated with gemcitabine in routine clinical practice.
A prospective cohort study following 400+ patients with advanced solid tumors treated with gemcitabine, with pre-treatment 9p21 status assessed by NGS, tracking response rates, time to progression, and survival over 3 years, adjusting for tumor type and prior therapies.
A case-control study could compare the frequency of 9p21 loss in patients who responded to gemcitabine versus those who did not.
A case-control study comparing 120 patients with advanced bladder cancer who achieved partial or complete response to gemcitabine (cases) versus 120 non-responders (controls), matched for stage and prior therapy, with retrospective 9p21 deletion status assessed by FISH.
A cross-sectional analysis could correlate 9p21 deletion status with immediate morphological or radiographic response to gemcitabine in a clinical population.
A cross-sectional analysis of 200+ patients with advanced cancer receiving gemcitabine, measuring 9p21 deletion status via biopsy and correlating it with radiographic response (RECIST) at 8 weeks, adjusting for tumor type and line of therapy.